Analysts Set STAAR Surgical (NASDAQ:STAA) PT at $42.83

Shares of STAAR Surgical (NASDAQ:STAA) have earned an average recommendation of “Hold” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $42.83.

A number of equities research analysts recently commented on STAA shares. Canaccord Genuity Group lowered their price target on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a report on Monday, December 9th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Stifel Nicolaus lowered their price objective on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, August 26th. Finally, Stephens upgraded shares of STAAR Surgical to a “hold” rating in a research report on Monday, December 2nd.

STAAR Surgical Price Performance

Shares of STAA stock opened at $24.86 on Thursday. STAAR Surgical has a one year low of $24.21 and a one year high of $52.68. The company has a market cap of $1.23 billion, a P/E ratio of 56.50 and a beta of 0.59. The firm has a 50-day moving average of $28.91 and a 200-day moving average of $34.97.

Hedge Funds Weigh In On STAAR Surgical

Large investors have recently modified their holdings of the company. Van ECK Associates Corp boosted its holdings in STAAR Surgical by 12.7% during the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after acquiring an additional 393 shares during the period. Sei Investments Co. grew its holdings in shares of STAAR Surgical by 2.7% in the second quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier’s stock worth $718,000 after purchasing an additional 394 shares during the last quarter. Creative Planning increased its stake in shares of STAAR Surgical by 8.0% in the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock worth $205,000 after buying an additional 408 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of STAAR Surgical by 3.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock worth $540,000 after buying an additional 418 shares during the period. Finally, Louisiana State Employees Retirement System raised its holdings in STAAR Surgical by 2.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 24,700 shares of the medical instruments supplier’s stock valued at $1,176,000 after buying an additional 500 shares during the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.